Paolo Tarantino: ADCs keep shortening the distance between oncology fields

Paolo Tarantino shared a post on X:

“ADCs keep shortening the distance between oncology fields. The HER2-low experience in breast oncology, the dual ADC in GU, and the ADC combos tested in GI and thoracic oncology, all expand our knowledge of these important drugs.

Thanks to Ryan Flinn for this interview!”

Read further
Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.